Yubo International Biotech Limited (YBGJ)

Yubo International Biotech Limited (YBGJ) Healthcare & Pipeline Overview

Yubo International Biotech Limited, headquartered in Beijing, China, specializes in endometrial stem cell research and applications, complemented by a diverse portfolio including respiratory, skincare, and personal care products. Operating under the VIVCELL brand for specialized stem cell services, the company navigates the healthcare sector with a focus on innovative biotech solutions and health management consulting.

What Is the Investment Thesis for YBGJ?

Yubo International Biotech Limited (YBGJ) presents an investment profile centered on its dual focus in advanced biotechnology and diversified consumer health products. The company's primary dedication to endometrial stem cell research and application positions it within a high-potential, albeit nascent, segment of the healthcare sector. This core R&D effort, coupled with specialized VIVCELL brand services like cellular analysis and health management consulting, aims to capitalize on the growing demand for innovative biotech solutions and personalized medicine. Financially, YBGJ currently operates with a Market Cap of 851K and a Gross Margin of 15.8%, indicating some revenue generation capacity. However, a significant Profit Margin of -681.8% highlights substantial operational losses, while a Beta of 0.64 suggests lower volatility relative to the broader market. The company's diverse product lines, including respiratory health, skincare, and nutritious beverages, offer potential revenue diversification. As an OTC Other listed company, YBGJ faces inherent risks such as limited liquidity and information availability, requiring investors to closely monitor financial filings and industry developments for insights into its strategic execution and progress in commercializing its biotech innovations.

Based on FMP financials and quantitative analysis

YBGJ Key Highlights

• The company maintains a Gross Margin of 15.8%, indicating the profitability of its core product sales before operating expenses.
• Yubo International Biotech Limited recorded a Profit Margin of -681.8%, reflecting significant operational losses relative to its revenue.
• With a Market Cap of 851K, the company currently holds a very small market valuation, typical for early-stage or thinly traded entities.
• The company's Beta is 0.64, suggesting its stock price has historically been less volatile than the overall market.
• YBGJ operates with a lean structure, employing 18 individuals, which influences its operational scale and capacity for R&D and product diversification.

Who Are YBGJ's Competitors?

YBGJ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are YBGJ's Key Strengths?

• Core focus on endometrial stem cell research and development, positioning the company in an innovative biotech field.
• Diversified product portfolio across respiratory health, skincare, hair care, nutritious beverages, and personal care, offering multiple revenue streams.
• Specialized stem cell services under the VIVCELL brand, catering to personalized health management.
• Strategic presence in Beijing, China, a significant market for healthcare and biotech innovation.
• Lean operational structure with 18 employees, potentially allowing for agility in R&D.

What Are YBGJ's Weaknesses?

• Negative Profit Margin of -681.8% indicates significant unprofitability and operational challenges.
• Market Capitalization of 851K suggests a very small market presence and limited access to capital.
• Operating on the OTC Other tier, which implies limited liquidity and information availability for investors.
• Small employee base of 18 may limit the scale and pace of R&D and commercialization efforts.
• Disclosure status is 'Unknown', creating uncertainty for investors regarding financial transparency.

What Could Drive YBGJ Stock Higher?

• Successful advancement of endometrial stem cell research into preclinical or clinical trial phases, demonstrating therapeutic potential.
• Introduction of new, commercially viable products within its diversified portfolio, such as advanced skincare formulations or functional beverages.
• Expansion of the VIVCELL brand's services to include new diagnostic tools or health management programs, attracting a broader client base.
• Strategic partnerships or collaborations with academic institutions or larger biotech firms to accelerate research and development efforts.
• Efforts to improve financial transparency and disclosure, potentially leading to an upgrade in OTC tier classification.

What Are the Key Risks for YBGJ?

• Financial-distress signal — its Altman Z-Score of -24.98 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Significant unprofitability, as evidenced by a -681.8% Profit Margin, posing a risk to long-term financial viability without substantial capital infusion.
• High regulatory hurdles and lengthy approval processes inherent in stem cell research, which could delay or prevent commercialization of therapies.
• Limited liquidity and information availability due to OTC Other listing and 'Unknown' disclosure status, increasing investment risk.
• Intense competition in both the biotech and consumer health markets from larger, more established companies with greater resources.
• Dependence on successful R&D outcomes for endometrial stem cells, where failure to achieve desired results could undermine the company's core strategy.

What Are the Growth Opportunities for YBGJ?

• Growth opportunity 1: Expansion of Endometrial Stem Cell Applications. Yubo International Biotech's primary focus on endometrial stem cell research and application represents a significant long-term growth driver. The global regenerative medicine market, which includes stem cell therapies, is projected to reach substantial valuations, with estimates often exceeding $50 billion by the early 2030s. As research progresses, the company could develop new therapeutic applications for various medical conditions, potentially addressing unmet needs in areas like reproductive health, tissue repair, or autoimmune diseases. Successful clinical development and regulatory approvals for these applications would unlock access to large, high-value markets, establishing YBGJ as a key player in a specialized biotech niche.
• Growth opportunity 2: Broadening the VIVCELL Brand Service Portfolio. The VIVCELL brand currently offers specialized stem cell services, including cellular analysis and health management consulting. There is a substantial and growing market for personalized health and wellness services, driven by increasing consumer awareness and technological advancements. By expanding the range of services under VIVCELL, such as advanced genetic testing, personalized wellness plans, or integration with digital health platforms, YBGJ could capture a larger share of this market. This expansion could involve partnerships with clinics or wellness centers, enhancing brand visibility and service accessibility, and creating recurring revenue streams from a health-conscious clientele seeking tailored solutions.
• Growth opportunity 3: Geographic Expansion for Diversified Products. While headquartered in Beijing, China, the company's diverse product lines—respiratory health solutions, skincare, hair care, nutritious beverages, and personal care items—offer avenues for geographic expansion beyond its current operational scope. The global markets for these consumer health and wellness products are vast, with skincare alone exceeding $150 billion annually and nutritious beverages showing consistent growth. By strategically entering new regional markets in Asia, Europe, or North America, YBGJ could tap into new consumer bases and distribution channels. This would require careful market analysis, regulatory compliance, and localized marketing strategies to adapt products to specific cultural preferences and consumer demands.
• Growth opportunity 4: Leveraging Demand for Innovative Biotech Solutions. The AI insight highlights a 'growing demand for innovative biotech solutions,' which YBGJ is positioned to address through its core stem cell research. This opportunity involves not only developing new therapies but also potentially licensing its proprietary research or intellectual property to larger pharmaceutical companies. The global biotechnology market is expected to continue its robust growth, driven by scientific breakthroughs and increasing investment in R&D. By demonstrating efficacy and safety in its stem cell applications, YBGJ could attract strategic partnerships, joint ventures, or even acquisition interest, providing capital and resources for further development and commercialization.
• Growth opportunity 5: Product Line Extension within Existing Categories. Yubo International Biotech can achieve growth by further extending its product lines within its established categories. For instance, in skincare, the company could introduce anti-aging lines, specialized treatments for sensitive skin, or products targeting specific dermatological concerns. In nutritious beverages, it could develop new functional drinks, plant-based options, or products fortified with specific vitamins and minerals, catering to evolving dietary trends. This strategy allows the company to leverage existing brand recognition and distribution networks, reducing market entry costs compared to entirely new categories. Continuous innovation and product differentiation within these segments can enhance market share and customer loyalty.

What Opportunities Does YBGJ Have?

• Growing global demand for innovative biotech solutions, particularly in regenerative medicine and stem cell therapies.
• Expansion of the VIVCELL brand's specialized services to capture a larger share of the personalized health and wellness market.
• Potential for geographic expansion of its diversified consumer product lines into new regional markets.
• Strategic partnerships or licensing agreements for its endometrial stem cell research with larger pharmaceutical entities.
• Product line extensions within existing categories (e.g., new skincare formulations, functional beverages) to increase market penetration.

What Threats Does YBGJ Face?

• Intense competition from established pharmaceutical companies and larger biotech firms with greater resources.
• Significant regulatory hurdles and lengthy approval processes inherent in stem cell research and drug development.
• Challenges associated with OTC listing, including difficulty in raising capital and maintaining investor interest.
• Potential for negative public perception or ethical concerns surrounding stem cell research.
• Economic downturns or changes in consumer spending habits impacting demand for non-essential personal care and wellness products.

What Are YBGJ's Competitive Advantages?

• Specialized focus on endometrial stem cell research and application, potentially leading to proprietary knowledge and intellectual property in a niche biotech area.
• Diversified product portfolio across consumer health and wellness, reducing reliance on a single product or market segment.
• The VIVCELL brand for specialized stem cell services, which could build brand recognition and trust in a high-value service sector.
• Expertise in both advanced biotechnology and consumer product development, allowing for a unique market position.
• Headquarters in Beijing, China, potentially offering strategic advantages in accessing local markets and talent within the Asian healthcare landscape.

What Does YBGJ Do?

Yubo International Biotech Limited, operating through its various subsidiaries from its headquarters in Beijing, China, is primarily dedicated to the research, development, and practical application of endometrial stem cells. This core focus positions the company within the burgeoning field of regenerative medicine, exploring the therapeutic potential of these unique cells. Beyond its specialized stem cell initiatives, Yubo International Biotech has strategically diversified its product offerings to address a broader spectrum of consumer health and wellness needs. The company provides a range of solutions for respiratory health, catering to an increasing global demand for products that support lung function and alleviate respiratory discomfort. Its portfolio further extends into the beauty and personal care segments, encompassing skincare and hair care formulations designed for various consumer demographics. Additionally, Yubo International Biotech manufactures nutritious beverages, tapping into the health-conscious consumer market, and offers personal care items tailored for both men and women, emphasizing daily hygiene and wellness. A significant component of its business model involves delivering specialized stem cell services, which include detailed cellular analysis and comprehensive health management consulting. These services are consolidated and offered under the proprietary VIVCELL brand, aiming to provide personalized health insights and guidance based on advanced biotechnological assessments. The company's operational structure, with its focus on both cutting-edge biotechnology and diversified consumer products, reflects an approach to capture value across multiple segments of the healthcare and wellness industries.

What Products and Services Does YBGJ Offer?

• Conduct research and development focused on endometrial stem cells for potential therapeutic applications.
• Provide specialized stem cell services, including cellular analysis, under the VIVCELL brand.
• Offer comprehensive health management consulting services through the VIVCELL brand.
• Manufacture and distribute solutions for respiratory health.
• Develop and market skincare and hair care formulations.
• Produce and sell nutritious beverages.
• Supply personal care items tailored for both men and women.
• Operate through various subsidiaries from its headquarters in Beijing, China.

How Does YBGJ Make Money?

• Revenue generation from the sale of diversified consumer health products, including respiratory solutions, skincare, hair care, nutritious beverages, and personal care items.
• Income derived from providing specialized stem cell services, such as cellular analysis, to individual clients or healthcare providers.
• Consulting fees earned through comprehensive health management services offered under the VIVCELL brand.
• Potential future revenue streams from the commercialization or licensing of endometrial stem cell therapies, contingent on research success and regulatory approvals.
• Operating through a subsidiary structure, allowing for specialized focus within different product and service segments.

What Industry Does YBGJ Operate In?

Yubo International Biotech Limited operates within the Medical - Instruments & Supplies industry, a segment of the broader Healthcare sector characterized by innovation and stringent regulatory oversight. The company's core focus on endometrial stem cell research places it within the rapidly evolving biotechnology landscape, specifically regenerative medicine. This niche is experiencing increasing demand for novel therapeutic solutions, driven by advancements in cellular biology and a growing aging population. While the overall healthcare market is robust, YBGJ's diversified product portfolio, including respiratory health, skincare, and nutritious beverages, positions it across various consumer health segments. The competitive landscape includes established pharmaceutical giants, specialized biotech firms, and consumer goods companies. YBGJ aims to carve out its position by leveraging its specialized stem cell expertise and the VIVCELL brand, while navigating the challenges of being a smaller player in a capital-intensive and highly competitive industry. The company's ability to translate its research into commercially viable products and services will be critical for its market penetration and growth.

Who Are YBGJ's Key Customers?

• Individuals seeking advanced cellular analysis and personalized health management consulting services through the VIVCELL brand.
• Consumers looking for respiratory health solutions to support lung function and alleviate discomfort.
• Customers interested in skincare and hair care products for beauty and personal grooming.
• Health-conscious individuals purchasing nutritious beverages for dietary and wellness benefits.
• General consumers of personal care items for daily hygiene and self-care needs.

Company Profile

Yubo International Biotech Limited operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Yang Wang. YBGJ has traded publicly since 2021.

How Yubo International Biotech Limited Is Valued

Yubo International Biotech Limited carries a market capitalization of 851K, placing it in the micro-cap category. Relative to its peer group, YBGJ's quantitative score of 48/100 is below the peer average of 62/100.

ROE 37%Key Financial Metrics

Return on equity for Yubo International Biotech Limited stands at 37.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -28.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.20 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -75.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Yubo International Biotech Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -24.98 places it in the distress zone, a signal of elevated financial risk.

YBGJ Financials

YBGJ Latest News

No recent news available for YBGJ.

YBGJ Analyst Consensus

YBGJ MoonshotScore

Common Questions About YBGJ (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources